344 related articles for article (PubMed ID: 23618382)
1. Organometallic Iridium(III) anticancer complexes with new mechanisms of action: NCI-60 screening, mitochondrial targeting, and apoptosis.
Hearn JM; Romero-Canelón I; Qamar B; Liu Z; Hands-Portman I; Sadler PJ
ACS Chem Biol; 2013; 8(6):1335-43. PubMed ID: 23618382
[TBL] [Abstract][Full Text] [Related]
2. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
3. Potential anticancer agent for selective damage to mitochondria or lysosomes: Naphthalimide-modified fluorescent biomarker half-sandwich iridium (III) and ruthenium (II) complexes.
Ma W; Zhang S; Tian Z; Xu Z; Zhang Y; Xia X; Chen X; Liu Z
Eur J Med Chem; 2019 Nov; 181():111599. PubMed ID: 31408807
[TBL] [Abstract][Full Text] [Related]
4. Half-Sandwich Iridium(III) and Ruthenium(II) Complexes Containing P^P-Chelating Ligands: A New Class of Potent Anticancer Agents with Unusual Redox Features.
Li J; Tian M; Tian Z; Zhang S; Yan C; Shao C; Liu Z
Inorg Chem; 2018 Feb; 57(4):1705-1716. PubMed ID: 29400963
[TBL] [Abstract][Full Text] [Related]
5. Mechanism of cellular accumulation of an iridium(III) pentamethylcyclopentadienyl anticancer complex containing a C,N-chelating ligand.
Novohradsky V; Liu Z; Vojtiskova M; Sadler PJ; Brabec V; Kasparkova J
Metallomics; 2014 Mar; 6(3):682-90. PubMed ID: 24448555
[TBL] [Abstract][Full Text] [Related]
6. Organometallic half-sandwich iridium anticancer complexes.
Liu Z; Habtemariam A; Pizarro AM; Fletcher SA; Kisova A; Vrana O; Salassa L; Bruijnincx PC; Clarkson GJ; Brabec V; Sadler PJ
J Med Chem; 2011 Apr; 54(8):3011-26. PubMed ID: 21443199
[TBL] [Abstract][Full Text] [Related]
7. Anticancer effect evaluation in vitro and in vivo of iridium(III) polypyridyl complexes targeting DNA and mitochondria.
Zhang H; Tian L; Xiao R; Zhou Y; Zhang Y; Hao J; Liu Y; Wang J
Bioorg Chem; 2021 Oct; 115():105290. PubMed ID: 34426145
[TBL] [Abstract][Full Text] [Related]
8. Photoinduced anticancer activity studies of iridium(III) complexes targeting mitochondria and tubules.
Zhang WY; Yi QY; Wang YJ; Du F; He M; Tang B; Wan D; Liu YJ; Huang HL
Eur J Med Chem; 2018 May; 151():568-584. PubMed ID: 29656200
[TBL] [Abstract][Full Text] [Related]
9. Ester-Modified Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents.
Wang FX; Chen MH; Hu XY; Ye RR; Tan CP; Ji LN; Mao ZW
Sci Rep; 2016 Dec; 6():38954. PubMed ID: 27958338
[TBL] [Abstract][Full Text] [Related]
10. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
11. Anticancer and antibacterial activity in vitro evaluation of iridium(III) polypyridyl complexes.
Yi QY; Zhang WY; He M; Du F; Wang XZ; Wang YJ; Gu YY; Bai L; Liu YJ
J Biol Inorg Chem; 2019 Mar; 24(2):151-169. PubMed ID: 30564887
[TBL] [Abstract][Full Text] [Related]
12. Pharmaco-genomic investigations of organo-iridium anticancer complexes reveal novel mechanism of action.
Hearn JM; Hughes GM; Romero-Canelón I; Munro AF; Rubio-Ruiz B; Liu Z; Carragher NO; Sadler PJ
Metallomics; 2018 Jan; 10(1):93-107. PubMed ID: 29131211
[TBL] [Abstract][Full Text] [Related]
13. Antitumor Effects of Ir(III)-2
Panchangam RL; Rao RN; Balamurali MM; Hingamire TB; Shanmugam D; Manickam V; Chanda K
Inorg Chem; 2021 Dec; 60(23):17593-17607. PubMed ID: 34767343
[TBL] [Abstract][Full Text] [Related]
14. Organoiridium complexes: anticancer agents and catalysts.
Liu Z; Sadler PJ
Acc Chem Res; 2014 Apr; 47(4):1174-85. PubMed ID: 24555658
[TBL] [Abstract][Full Text] [Related]
15. Organometallic rhodium(III) and iridium(III) cyclopentadienyl complexes with curcumin and bisdemethoxycurcumin co-ligands.
Pettinari R; Marchetti F; Pettinari C; Condello F; Petrini A; Scopelliti R; Riedel T; Dyson PJ
Dalton Trans; 2015 Dec; 44(47):20523-31. PubMed ID: 26548708
[TBL] [Abstract][Full Text] [Related]
16. Hydrosulfide Adducts of Organo-Iridium Anticancer Complexes.
Štarha P; Habtemariam A; Romero-Canelón I; Clarkson GJ; Sadler PJ
Inorg Chem; 2016 Mar; 55(5):2324-31. PubMed ID: 26863200
[TBL] [Abstract][Full Text] [Related]
17. Novel half-sandwich iridium(iii) imino-pyridyl complexes showing remarkable in vitro anticancer activity.
Li J; Guo L; Tian Z; Tian M; Zhang S; Xu K; Qian Y; Liu Z
Dalton Trans; 2017 Nov; 46(44):15520-15534. PubMed ID: 29090698
[TBL] [Abstract][Full Text] [Related]
18. Mitochondria-targeted phosphorescent cyclometalated iridium(III) complexes: synthesis, characterization, and anticancer properties.
Li Y; Liu B; Xu CX; He L; Wan YC; Ji LN; Mao ZW
J Biol Inorg Chem; 2020 Jun; 25(4):597-607. PubMed ID: 32232583
[TBL] [Abstract][Full Text] [Related]
19. Half-sandwich iridium(III) complexes with α-picolinic acid frameworks and antitumor applications.
Hao H; Liu X; Ge X; Zhao Y; Tian X; Ren T; Wang Y; Zhao C; Liu Z
J Inorg Biochem; 2019 Mar; 192():52-61. PubMed ID: 30597449
[TBL] [Abstract][Full Text] [Related]
20. Configurationally regulated half-sandwich iridium(III)-ferrocene heteronuclear metal complexes: Potential anticancer agents.
Liu X; Wang Z; Zhang X; Lv X; Sun Y; Dong R; Li G; Ren X; Ji Z; Yuan XA; Liu Z
J Inorg Biochem; 2023 Dec; 249():112393. PubMed ID: 37806004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
